Abstract:The shotgun proteomic based on the approach of tandem mass tag (TMT) labeling has received increasing attention for neuroproteomics analysis and becomes an effective tool for the identification and quantification of a large number of proteins for the purpose of revealing key proteins involved in the neuronal dysfunction and an inflammatory response associated with neurodegenerative disorders. To assess the potential expression difference of proteins in cerebrospinal fluids (CSF) between Creutzfeldt–Jakob disease (CJD) and non-CJD patients, the pooled CSF samples from 39 Chinese probable sporadic CJD (sCJD) patients and from 52 non-CJD cases were comparably analyzed with the methodology of TMT labeling and RP-RP-UPLC-MS/MS. Totally, 437 possible proteins were identified in the tested CSF specimen, among them, 49 proteins with 95 % confidence interval. Differential assays showed among those 49 CSF proteins, 12 were upregulated and 13 were downregulated significantly in the sCJD compared to non-CJD. The most affected pathway of the differential expression proteins in CSF of sCJD was complement and coagulation cascade. Western blots for six selected changed proteins in the pooled CSF samples revealed the similar altering profiles in the groups of sCJD and non-CJD as proteomics. Furthermore, CSF samples from 24 CJD patients and 24 non-CJD patients were randomly selected and subjected individually into the Western blots of an increased protein (phosphoglycerate mutase 1) and a decreased one (alpha-1-antichymotrysin), which also confirmed the altering tendency of these identified proteins. Those data indicate that proteomic assay of CSF is a powerful technique not only for selection of the potential biomarkers for the development of diagnostic tool of CJD but also for supplement of useful scientific clues for understanding the CSF homeostasis during the pathogenesis of prion diseases.

Expression of tetranectin in cerebrospinal fluid of patients with Parkinson's disease

Analysis of Cerebrospinal Fluid Protein Expression in Parkinson's Disease by Two-Dimensional Difference Gel Electrophoresis

Expression of Tetranectin in the Cerebrospinal Fluid of Patients with Parkinson Disease Pre- and Post-Dbs

Global Protein Differential Expression Profiling of Cerebrospinal Fluid Samples Pooled from Chinese Sporadic CJD and non-CJD Patients

Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders.

Identification of Glycoproteins in Human Cerebrospinal Fluid with a Complementary Proteomic Approach

Comparative Peptidome Analyses of the Profiles of the Peptides Ranging from 1-10 KD in CSF Samples Pooled from Probable Sporadic CJD and Non-Cjd Patients.

Altered microRNA profiles in cerebrospinal fluid exosome in Parkinson disease and Alzheimer disease.

Central Nervous System-Derived Exosomal Alpha-Synuclein in Serum May Be a Biomarker in Parkinson's Disease.

Tetranectin is a potential biomarker in cerebrospinal fluid and serum of patients with epilepsy

Proteomic Identification of a Stress Protein, Mortalin/mthsp70/GRP75

Proteomic Identification Of A Stress Protein, Mortalin/Mthsp70/Grp75 - Relevance To Parkinson Disease

Quantitative Proteomic Analysis of Serum Proteins in Patients with Parkinson'S Disease Using an Isobaric Tag for Relative and Absolute Quantification Labeling, Two-Dimensional Liquid Chromatography, and Tandem Mass Spectrometry

Identification of Distinct Blood-Based Biomarkers in Early Stage of Parkinson’s Disease

Molecular Features of Parkinson's Disease in Patient‐Derived Midbrain Dopaminergic Neurons

Proteomic analysis of the cerebrospinal fluid in multiple sclerosis and neuromyelitis optica patients.

Proteome analysis of the sera from Chinese Parkinson's disease patients.

Evaluation of plasma levels of NFL, GFAP, UCHL1 and tau as Parkinson's disease biomarkers using multiplexed single molecule counting

Tetranectin Gene Deletion Induces Parkinson's Disease by Enhancing Neuronal Apoptosis

Correlations between CSF proteins and spontaneous neuronal activity in Parkinson's disease.

Intracranial Lipomas in Neonate